ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

News

News

Adding bevacizumab to paclitaxel did not improve outcomes in a phase II trial of patients with angiosarcoma.

Daratumumab, a monoclonal antibody that targets CD38, was safe and effective in patients with heavily pretreated and refractory multiple myeloma.

Tracking tumor DNA in the blood of early breast cancer patients following surgery predicted relapse nearly 8 months earlier than conventional imaging.

Beta-blockers were associated with increased overall survival in women with epithelial ovarian cancer, according to a retrospective study.

A complex high-dose combination therapy is tolerable and effective in patients with aggressive B-cell lymphoma that has spread to the central nervous system.

A large study found that while the risk of dying from breast cancer after a DCIS diagnosis is quite low, it is on par with that of women diagnosed with small, invasive breast tumors, and that aggressive DCIS treatment does not produce better results.

The presence of the truncated form of human epidermal growth factor receptor 2 (p95HER2) in circulating tumor cells is associated with poor survival in breast cancer patients.

Pages

Subscribe to News on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.